Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.

Melanoma research - 1 Oct 2014

Uribe Pablo, Anforth Rachael M, Kefford Richard F, Fernandez-Peñas Pablo

Abstract excerpt

BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) increase survival in BRAF mutant metastatic melanoma patients; however, they induce a well-known spectrum of cutaneous side effects during treatment. Whereas the BRAFi dabrafenib induces cutaneous squamous cell carcinomas and verrucal keratosis, t...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Drug Administration Schedule
Share to Fatal Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Source

Identifiers

PMID: 24922191
DOI: 10.1097/CMR.0000000000000096

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24922191-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acneiform eruption in a patient with metastatic melanoma after ceasing combination dabrafenib/trametinib therapy.PMID 24922191Read ↗

Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Semantic proximity Read ↗

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.Semantic proximity Read ↗

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.Semantic proximity Read ↗

[Unusual association of BRAF and MEK inhibitors: Clinical response of metastatic melanoma treated with dabrafenib-cobimetinib].Semantic proximity Read ↗

Eruptive naevi associated with encorafenib for metastatic colorectal cancer: two cases.Semantic proximity Read ↗

Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.Semantic proximity Read ↗

BRAFV600E mutation status of involuting and stable nevi in dabrafenib therapy with or without trametinib.Semantic proximity Read ↗

[Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].Semantic proximity Read ↗

Dermatological approach to vemurafenib skin toxicity: a single centre experience.Semantic proximity Read ↗

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.